Womble Bond Dickinson (WBD) has advised Camden Partners Nexus, a Baltimore-based venture capital firm with a focus on biomedical technology companies, on its participation in an $80m series B investment round in COMPASS Pathways.
COMPASS Pathways, a London-based mental health organisation, will use the funding to expand on its lead programme in psilocybin therapy for treatment-resistant depression. It will also support further research and advance the company's preclinical pipeline, develop digital technologies and help establish new academic and clinical research partnerships.
Leon Miller, partner, commented:
"It was a pleasure working with our US colleagues to advise Camden Partners Nexus on this Series B investment. Our strong credentials in venture capital coupled with our unique transatlantic offering enabled us to provide the best possible outcome for our client."
Ranking in the UK's top 20 law firms, WBD provides legal expertise in eleven key sectors from across eight offices in the UK, including London, and 19 offices in the US. The firm has a large corporate practice in the UK advising national and international clients on a broad range of corporate transactions, particularly M&A, IPOs, private equity investments as well as growth and development capital fundraisings.